ReachMD CME

CME credits: 0.25 Valid until: 23-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-evidence-into-action-nonsteroidal-mras-in-patients-with-hf/49259/ In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case, the faculty review evolving recommendations supporting finerenone as part of guideline-directed medical therapy, along with evidence from FINEARTS-HF and related analyses. The discussion highlights considerations for early initiation, use in combination with SGLT2 inhibitors, patient selection, dosing and monitoring, and management of potassium and renal function changes in clinical practice.=

CME credits: 0.50 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/fxia-remix-keeping-the-flow-without-missing-a-beat/54142/ Can an antithrombotic meaningfully reduce the risk of recurrent ischemic stroke without increasing major bleeding? Drs. Mike Sharma, Ashkan Shoamanesh, and Brian Mac Grory explore the science behind factor XIa inhibition and its potential to decouple thrombosis from hemostasis. The panel reviews pivotal OCEANIC-STROKE results presented at ISC 2026, highlighting a 26% relative risk reduction in ischemic stroke without an observed increase in ISTH major bleeding. They examine outcomes across stroke subtypes and place these results in context with other agents in development, such as milvexian and abelacimab. This conversation considers whether factor XI inhibition may alter long-standing assumptions about the tradeoff between efficacy and safety in secondary stroke prevention.=

CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/brain-metastases-management-from-detection-to-multidisciplinary-care/56517/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/first-line-management-of-hrher2-low-breast-cancer-with-brain-metastases/56519/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

CME credits: 1.00 Valid until: 07-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/egfr-mutated-nsclc-with-brain-metastases-navigating-adc-treatment-decisions/56521/ What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/ibd-beyond-symptoms-what-community-gis-need-to-know/54127/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/targeting-inflammation-in-ibd-localized-vs-systemic-strategies/56890/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/understanding-the-microbiomes-role-in-ibd-management/56892/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 01-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/putting-it-all-together-challenges-addressed/56894/ This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/emerging-focus-in-naion-sharpening-diagnostic-precision-for-tomorrows-treatments/49222/ This program addresses critical practice gaps in the evaluation and management of non-arteritic anterior ischemic optic neuropathy (NAION). Faculty will review acute ischemic pathophysiology, diagnostic variability, and structured approaches to improve diagnostic accuracy and readiness for clinical trials. Through case-based discussions, participants will learn how to identify key mimickers (eg, optic neuritis, AION) through targeted testing, apply evidence-based evaluation pathways, improve documentation practices, and recognize referral scenarios.The program will also highlight the impact of systemic risk factors, including GLP-1 receptor agonists, and provide the latest data on investigational agents like cenegermin and privosegtor. Designed for neuro-ophthalmologists, ophthalmologists, and neurologists, this activity supports enhanced diagnostic precision, informed patient counseling, and preparation for emerging NAION therapies.=

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/Catching-Demodex-in-the-Act/56703/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-missed-diagnosis-a-45-year-old-software-engineer-who-complains-of-dry-eyes/56705/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-neverending-journey-a-66-year-old-patient-who-has-undergone-several-rounds-of-tea-tree-oilbased-treatment/56707/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.